Shkreli hearing angered a lot of people - analyst

Unfortunately, Shkreli hearing on Capitol Hill will evoke calls for price control in pharmaceuticals in general, says Yevgeniy Feyman, fellow and deputy director at Manhattan Institute. Bobbi Rebell reports.